Cargando…

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue

Despite representing some of the most common and investigated molecular changes in intrahepatic cholangiocarcinoma (iCCA), the prognostic role of FGFR and IDH1/2 alterations still remains an open question. In this review we provide a critical analysis of available literature data regarding this topi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brandi, Giovanni, Deiana, Chiara, Galvani, Linda, Palloni, Andrea, Ricci, Angela Dalia, Rizzo, Alessandro, Tavolari, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164916/ https://www.ncbi.nlm.nih.gov/pubmed/37168376 http://dx.doi.org/10.3389/fonc.2023.1137510

Ejemplares similares

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
por: Deiana, Chiara, et al.
Publicado: (2023)

Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
por: Vasuri, Francesco, et al.
Publicado: (2023)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
por: Brandi, Giovanni, et al.
Publicado: (2022)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review
por: Tavolari, Simona, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2023)

Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma
por: Nanni, Cristina, et al.
Publicado: (2023)

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
por: Brandi, Giovanni, et al.
Publicado: (2015)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
por: Rimini, Margherita, et al.
Publicado: (2022)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2021)

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma
por: Peraldo-Neia, C., et al.
Publicado: (2018)

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
por: Xiang, Xiao, et al.
Publicado: (2021)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
por: Zhang, Lei, et al.
Publicado: (2023)

The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma—unveiling the future challenges in drug therapy
por: Nishida, Naoshi
Publicado: (2023)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Opisthorchiasis and cholangiocarcinoma in Southeast Asia: an unresolved problem
por: Hughes, Thomas, et al.
Publicado: (2017)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features
por: Lee, Kyoungbun, et al.
Publicado: (2020)

Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma
por: Zhu, Yong, et al.
Publicado: (2021)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
por: Salati, Massimiliano, et al.
Publicado: (2021)

Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review
por: Bisello, Silvia, et al.
Publicado: (2021)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
por: Sumbly, Vikram, et al.
Publicado: (2022)

Preterm birth, an unresolved issue
por: Belizán, Jose M, et al.
Publicado: (2013)

Unresolved basic issues in hepatology
por: Weiskirchen, Ralf, et al.
Publicado: (2021)

Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster
por: Brandi, Giovanni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_chari48632bumd49rgk95btqei